In the management of pancreatic ductal adenocarcinoma, a dihydroartemisinic-derived nanoparticle conjugated with RSL3 has been reported to be administered in combination with programmed cell death ligand 1 (PD-L1) blockade therapy [37]. The gene discussed is CD274; the disease is pancreatic ductal adenocarcinoma.